For instance, TNF-α inhibitors (adalimumab, etanercept, and infliximab) and IL-12/IL-23 inhibitors (ustekinumab and guselkumab) have been linked to CTCL development in various studies (3). Here, TNF is linked to primary cutaneous T-cell non-Hodgkin lymphoma.